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Abstract
Bipolar disorder (BD) and schizophrenia (SZ) are known to share common genetic and psychosocial risk factors.
A recent epigenome-wide association study performed on blood samples from SZ patients found significant
hypomethylation of FAM63B in exon 9. Here, we used iPLEX-based methylation analysis to investigate two CpG
sites in FAM63B in blood samples from 459 BD cases and 268 controls. Both sites were significantly hypomethylated
in BD cases (lowest p value = 3.94 × 10−8). The methylation levels at the two sites were correlated, and no strong
correlation was found with nearby single nucleotide polymorphisms (SNPs), suggesting that methylation differences
at these sites are not readably picked up by genome-wide association studies. Overall, FAM63B hypomethylation was
found in BD patients, thus replicating the initial finding in SZ patients. This study suggests that FAM63B is a shared
epigenetic risk gene for the two disorders.
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Introduction
Bipolar disorder (BD) and schizophrenia (SZ) are severe
complex mental disorders known to have common gen-
etic [1] and psychosocial risk factors [2], as well as overlap
in some of their symptoms [3]. Together they are classi-
fied as major psychosis and contribute significantly to the
global burden of disease [4]. Several studies have investi-
gated differences in DNA methylation between individuals
with major psychosis and healthy controls in various
tissues and associated this epigenetic modification with
psychiatric phenotype [5–8]. A recent sequencing-based
epigenome-wide association study (EWAS) performed on
blood samples from 759 SZ cases and 738 control individ-
uals identified differential DNA methylation in family with
sequence similarity 63, member B (FAM63B) gene in a
region of exon 9 as their top EWAS finding (p value =
6.3 × 10−11), thereby becoming the first to implicate this
gene in a psychiatric disorder [9]. In the same publication,
the authors then used targeted bisulfite pyrosequencing of
three specific CpG sites in an 18 bp region of FAM63B to
follow up the top hit in an independent replication sample
of more than a thousands individuals. For all three CpG
sites, they obtained independent replication with p values
ranging from 2.76 × 10−12 (first CpG site in 18 bp region)
to 2.31 × 10−10 (last site in the 18 bp region) [9]. The
FAM63B gene spans 86 kb on chromosome 15q22.1, con-
tains nine exons in total and one CpG island that overlaps
with exon 1 (Fig. 1). The role of FAM63B in the patho-
physiology of SZ is unclear. Due to the high degree of
comorbidity between SZ and BD, as well as the established
evidence for shared genetic risk factors for the two disor-
ders [1, 10], it is highly relevant to investigate if the CpG
sites in SZ risk locus in FAM63B demonstrates the same
methylation pattern in BD. The aim of the study was to
determine if methylation FAM63B is associated with BD.
We used the Sequenom MassARRAY assays targeting spe-
cifically the two CpG sites identified as the sites of most
interest in SZ [9] to analyze DNA derived from whole
blood from 459 BD patients and 268 control individuals.
Methods
Study population
Bipolar disorder patients and control individuals were
collected at UCL and collaborating clinical centers.
Cases (n = 459) were Caucasian individuals who received
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clinical diagnoses of BD according to UK National
Health Service (NHS) psychiatrists at interview using
the categories of the International Classification of
Disease version 10 (ICD10). Control individuals (n =
268) were recruited from London branches of the Na-
tional Blood Service, from local NHS family doctor
clinics, and from university student volunteers. All
control individuals were interviewed with the Schizo-
phrenia and Affective Disorders Schedule-Life Time
version to exclude all psychiatric disorders [11]. The
sample is partly overlapping with the UCL sample de-
scribed in Sklar et al. [12]. The overlap is defined as all
individuals from the UCL sample where DNA was still
available and where the DNA was extracted from
whole blood (n = 587). Additional cases and controls
were included using similar inclusion criteria (n = 140),
reaching a sample size of 727 participants. For a de-
scription of the sample see Additional file 1: Table S1.
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Fig. 1 DNA methylation levels in cases and controls of two CpG sites in FAM63B exon 9 (lower panel). Gene structure of FAM63B and position of six
relevant SNPs (four genotyped from Affymetrix 500K array, a significant cis-mQTL (rs76751232), and one SNP associated with SZ in a genome-wide
association analysis (rs793571) [21]. The upper and lower hinges correspond to the 25th and 75th percentiles, while the whiskers extend from hinges
to the highest and lowest values within 1.5 * IQR (inter-quartile range)
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Ethics, consent, and permissions
The project was approved by the Metropolitan Multicenter
Research Ethics Committee, and all participants provided
written informed consent.
Methylation methods
Genomic DNA was bisulfite converted with the use of
EZ DNA Methylation Kit (Zymo Research, Freiburg,
Germany). The MassARRAY Designer tool in Typer 4.0
(Sequenom, San Diego, CA, USA) was used to design in-
dependent iPLEX assays for the same CpG sites as inves-
tigated in the Swedish EWAS study [9]. The FAM63B_1
assay targeted CpG at position chr15:5,9146,738 (hg19)
(corresponding to the first site in 18 bp region in Aberg
et al.), and FAM63B_2 targeted CpG site at position
chr15:59,146,756 (hg19) (corresponding to the last site
in 18 bp region in Aberg et al. [9]). The two CpG sites
are positioned 18 bp apart in exon 9 of FAM63B and are
not part of a CpG island (Fig. 1). Primers for iPLEX assays
can be found in Additional file 2: Table S2. Bisulfite
converted DNA samples were prepared according to the
iPLEX manufacturer’s protocol. The converted DNA
was dispensed onto a SpectroCHIPII and analyzed on a
MassARRAY workstation in the Allelotype mode
(Sequenom). Eighteen samples were independently bi-
sulfite converted and analyzed in duplicates for the
FAM63B_2 assay. This analysis demonstrated a good
overall consistency between duplicate samples (Additional
file 3: Figure S1). Additionally six samples were subjected
to pyrosequencing, demonstrating that the variation in
methylation levels for FAM63B_2 between individuals was
also evident with a different technology (Additional file
3: Figure S1). A regression analysis including BD group
status and gender was initially performed on logit-
transformed methylation. As the age distribution was
different between cases (mean = 47.7, SD = 12.4) and
controls (mean = 35.7, SD = 13.5), we tested for the effect
of age using regression analysis on logit-transformed
methylation in the control group and case group separ-
ately. In addition, a comparison of DNA methylation
between cases and controls was performed using a non-
parametric Mann-Whitney test. Each CpG site was ana-
lyzed independently, as well as in combination as a
differentially methylated region (DMR) by taking the
average of the methylation level of the two sites for each
individual. Finally, patients with bipolar I and II disorders
were compared using a nonparametric Mann-Whitney
test.
Genotypes, PCA, imputing, and mQTL analysis
Genotypes from the Affymetrix Gene Chip Human
Mapping 500K Array were available for 587 of the indi-
viduals, as they were part of a published genome-wide as-
sociation study [12]. Principle component analysis (PCA)
was performed using SmartPCA [13] with an LD-pruned
set of single nucleotide polymorphisms (SNPs) (R2 < 0.1,
39918 independent SNPs).
For cis methylation Quantitative Trait Loci (mQTL)
analysis, SNPs in FAM63B and an additional 5 kb up- and
downstream were imputed using Markov Chain Haplotyp-
ing software (MACH) [14]. Imputation was performed on
data from four genotyped SNPs in FAM63B (rs664936,
rs7164844, rs16940810 and rs4775096, all indicated at the
top of Fig. 1) and the 1000Genome phase 1 reference
panel. Genotype counts for the four genotyped SNPs
can be found in Additional file 4: Table S3. Imputed
SNPs were filtered by removing monomorphic markers
and those with an RSQ score ≤0.3. This resulted in a
final dataset of 173 imputed SNPs. To test for trans-
mQTL we performed an additional analysis that included
9071 genotyped SNPs on chromosome 15. For the trans-
mQTL analysis we filtered the results using an unadjusted
p value <0.05 and Δβ ≥ 0.1. All mQTL analyses were per-
formed using linear regression in PLINK [15].
Results
A regression analysis of methylation levels found signifi-
cant effect of affection status (p value = 7.92 × 10−8 for
FAM63B_1 and p value = 3.06°×°10−3 for FAM63B_2),
and no effect of gender (p value = 0.41 for FAM63B_1
and p value = 0.57 for FAM63B_2). No significant effect
of age on methylation was found in a regression ana-
lysis among the controls (lowest p value = 0.48) or cases
(lowest p value = 0.30).
In a direct comparison of cases and controls with Mann-
Whitney test we found significant DNA hypomethylation
in BD cases compared to controls (FAM63B_1 p value =
3.94 × 10−8, Δβ = −0.05 and FAM63B_2 p value = 8.59 × 10
−7, Δβ = −0.02) (Fig. 1). Consistent with these CpG sites be-
ing located 18 bp apart, the methylation levels at the two
sites were significantly correlated (Spearman correlation
rho = 0.64, p value <2.2 × 10−16). When analyzing the two
sites combined as a DMR, the region also displayed sig-
nificant hypomethylation in BD (p value = 6.85 × 10−6,
Δβ = −0.04). Overall, our BD data replicates the FAM63B
hypomethylation findings that had been reported in SZ.
The PCA found no evidence of population stratifica-
tion among the genotyped individuals (Additional file 5:
Figure S2), suggesting the differences were not driven by
ancestry stratification. No methylation differences were
found between bipolar I and bipolar II disorder patients,
but because of the small number of individuals with a
bipolar II diagnose, this may not be generalizable.
To investigate whether methylation levels were corre-
lated with nearby genotypes, we carried out mQTL ana-
lysis. In the cis-mQTL analysis, using only SNPs in the
near neighborhood, we found no significant mQTLs with
strong effects (β threshold ≥0.1). The most significant
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mQTL was found in exon 9 (imputed SNP rs76751232) for
FAM63B_2 (unadjusted p value = 0.011 and Δβ = −0.025
for the G allele). The full cis-mQTL analysis can be found
in Additional file 6: Table S4. In order to assess the effect
of trans-mQTLs, which are less frequent but can be
notable [16], an mQTL analysis was performed includ-
ing 9071 genotyped SNPs on chromosome 15. Again
using the thresholds (p value <0.05 and Δβ ≥ 0.1) analysis
revealed one nominally significant mQTL for FAM63B_1
(rs4774353 in FOXB1, chr15:60309674 (hg19), with p
value = 0.006 and Δβ = −0.11 for the A allele). Overall, this
suggests that the FAM63B methylation differences seen in
whole blood from BD and controls are not strongly driven
by SNPs in FAM63B, at least those that are on the Affy-
metrix 500K array. Of note, a potential mQTL may exist a
few genes upstream, in FOXB1, which needs further valid-
ation, as it can also be a false positive resulting from mul-
tiple testing.
Due to the relative large variation in methylation levels
observed in both groups, confirmed by technical replicates
and pyrosequencing, we speculated if differences in blood
cell composition could influence FAM63B methylation. In
the absence of methylation array data to estimate cell
composition in our sample, we instead downloaded a pub-
licly available Illumina 450K array methylation dataset for
nine different cell types from human whole blood [17].
The nearest probe cg21149266 (chr15:59,146,882 (hg19))
was positioned 126 bp downstream (3’) to FAM63B_2. Al-
though not ideal, the methylation level of cg21149266
may for this purpose serve as a reasonable proxy for our
two CpG sites, as methylation status of closely positioned
sites is often correlated. In the cell-specific dataset, the
methylation levels for cg21149266 were found to vary
markedly between cell types with highest level in B cells,
T cells, and NK cells, and lowest in monocytes, granulo-
cytes and neutrophils (Additional file 7: Figure S3). It is
thus possible that variation in cell composition contributes
to the variation in FAM63B methylation observed in the
entire dataset. If cell type heterogeneity is a systematic
confounder between cases and controls, the effect should
be shared across BD and SZ.
Discussion
We report FAM63B methylation to be significantly associ-
ated with BD, thus replicating the same finding recently
published for SZ [9], with consistency in genomic position
(same CpG sites) and direction (lower methylation in
cases) across both studies. This is of interest in the light of
phenotypic overlap between BD and SZ [18], with relatives
to BD patients having increased risk for developing SZ,
schizoaffective disorder or major depression [19, 20]. It
has also been shown that the two disorders share common
genetic risk variants, with a SNP co-heritability estimate
of 0.15 [1]. The discovery of shared epigenetic risk loci
across the two diseases, with differential methylation at
the same sites and in the same direction in the same tis-
sue, as in the case of FAM63B, may help progress the un-
derstanding of the shared etiology.
Interestingly, a large recent genome-wide association
study (GWAS) meta-analysis of SZ identified association
with FAM63B SNP, rs793571, as the most associated find-
ing in this gene (p value = 4.54 × 10−6) [21]. Rs793571 is
positioned in intron 7 of FAM63B (~5 kb from exon 9)
and could potentially affect methylation levels of the
18 bp region of interest. In our data, rs793571 was how-
ever not an mQTL for the two CpG sites and thus unlikely
to be involved in the methylation differences in the 18 bp
region of interest in blood, at least in our sample.
In general, we do not find strong local mQTLs for the
two investigated CpG sites in blood. In human fetal brain,
a recent study characterized systematically mQTLs and
found no Bonferroni-corrected mQTLs for FAM63B [16];
however, larger samples sizes across different tissues may
reveal robust mQTLs for FAM63B. The present literature
and data does in our opinion not imply that methylation
of this gene is strongly driven by genotypes of known
common SNPs, suggesting that methylation differences at
these sites are not readably picked up by GWAS. In the
near future, dense genotyping coupled with DNA methy-
lation and expression levels across different tissue and cell
types from projects like PsychENCODE [22] will help to
resolve whether the differences are driven by genetic vari-
ation or if they represent independent epigenetic signal.
The strength of the study was the use of the same
tissue and analysis of the exact same CpG sites, as iden-
tified as the top differentially methylated sites in the
large EWAS of SZ [9]. Also, we used a relatively large
sample of bipolar cases and controls, with genotypes
available for the majority of participants.
A limitation of this study is the possible confounder of
age. Because the BD cases in our study were slightly
older than controls, we analyzed the controls and cases
separately and found no effect of age on methylation at
this locus. Also, because the FAM63B hypomethylation
was initially identified in a large EWAS study of SZ [9],
and replicated in an independent sample, while adjusting
for age, we find it unlikely that the hypomethylation in
our study is driven by this covariate.
A second limitation is the possible confounder of
blood cell composition on methylation that we were
not able to correct for because of the candidate-gene
approach in this study. This limitation is not specific to
our study. While we acknowledge that cell heterogen-
eity may explain some of the variation in the entire
dataset (also among controls), it becomes a confounder
only if cell composition is systematically different in
cases. If cell composition is a confounder, it must be
shared between BD and SZ.
Starnawska et al. Clinical Epigenetics  (2016) 8:52 Page 4 of 6
Thirdly, medication could influence the methylation
levels of FAM63B. Interestingly, the use of mood-
stabilizing medication has been shown to influence the
DNA methylation patterns in blood in a recent study
by Houtepen and co-workers [23], using primarily the
Infinium HumanMethylation27 to measure methylation
levels. This array does not cover sites in FAM63B, so
the effect of medication on FAM63B methylation in BD
(and SZ) remains to be determined. It would be of great
interest in the future to collect medication information
(drug type, dosage and patient response). This not only
would permit correction for possible medication effects
in methylation data but also would also allow separ-
ation of the BD patients into pharmacological subphe-
notypes that could provide a link between methylation
signatures and medication response.
The biological function of FAM63B is currently not
well described. The gene is expressed across most tis-
sues, with highest expression in the cerebellar hemi-
sphere and cerebellum according to the genotype-tissue
expression (GTEx) portal [24] (Additional file 8: Figure
S4). In the BioGPS reference panel of normal human
tissues [25], high FAM63B expression was specifically
apparent in the pineal body (Additional file 9: Figure
S5), a small endocrine gland positioned in the center of
the brain. Interestingly, the pineal body is known to be
involved in producing and releasing melatonin which is
involved in the circadian clock [26]. Disruption of the cir-
cadian clock has been linked to the etiology of multiple
psychiatric disorders [27]. In the future, inclusion of infor-
mation on diurnal mood variation and sleeping patterns
of investigated individuals could allow for investigation of
possible correlations between DNA methylation levels of
FAM63B and the circadian clock.
In conclusion, we have identified FAM63B hypomethy-
lation in BD. Our data supports that FAM63B is a shared
epigenetic risk gene for BD and SZ.
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